Simona Bernardi, Giuseppina Ruggieri, Michele Malagola, Valeria Cancelli, Federica Cattina, Nicola Polverelli, Camilla Zanaglio, Simone Perucca, Federica Re, Alessandro Montanelli, and Domenico Russo
Philadelphia-positive (Ph+), BCR-ABL1, chronic myeloid leukemia (CML) is a model of leukemia driven by a single, specific, chromosome translocation, the t (9;22) (q22;q11). This translocation, leading to a new, hybrid, leukemia-specific gene (BCR-ABL1) encoding for a deregulated tyrosine-kinase protein (p210), drives the leukemic transformation of hematopoietic stem cells [1-6] and induces the progression of the disease from the early chronic phase (CP) to the late blastic phase BP) which close the natural history of the disease. In the 2000s, the introduction of Imatinib, the first tyrosinekinase inhibitor (TKI) able to target the protein p210, significantly changed the fate of CML to fatal disease in real chronic disease.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 